Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Sanjaykumar Hapani

Showing results (1-10 of 9) with videos related to

Pageof 1
Sort By:
The New England Journal of Medicine|June 28, 2013
Images in clinical medicine. Enlarged spleen with a heterogeneous patternRosa Nouvini, Sanjaykumar Hapani
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 4, 2011
Controversial role of bevacizumab in the development of venous thromboembolic eventsSanjaykumar Hapani, Shenhong Wu
Journal of Medical Case Reports|May 1, 2010
Eosinophilic pneumonia associated with bleomycin in a patient with mediastinal seminoma: a case reportSanjaykumar Hapani, David Chu, Shenhong Wu
The Lancet. Oncology|June 2, 2009
Risk of gastrointestinal perforation in patients with cancer treated with bevacizumab: a meta-analysisSanjaykumar Hapani, David Chu, Shenhong Wu
JAMA|February 3, 2011
Treatment-related mortality with bevacizumab in cancer patients: a meta-analysisVishal Ranpura, Sanjaykumar Hapani, Shenhong Wu
Acta Oncologica (Stockholm, Sweden)|February 17, 2010
Risk of cardiac ischemia and arterial thromboembolic events with the angiogenesis inhibitor bevacizumab in cancer patients: a meta-analysis of randomized controlled trialsVishal Ranpura, Sanjaykumar Hapani, Jeff Chuang, et al.
Oncology|November 6, 2010
Increased risk of serious hemorrhage with bevacizumab in cancer patients: a meta-analysisSanjaykumar Hapani, Amna Sher, David Chu, et al.
Acta Oncologica (Stockholm, Sweden)|April 19, 2013
Risk of liver toxicity with the angiogenesis inhibitor pazopanib in cancer patientsSamir Kapadia, Sanjaykumar Hapani, Toni K Choueiri, et al.
Journal of General Internal Medicine|November 27, 2012
Test results follow-up: a systematic reviewShai Gavi, Vishal Ranpura, Sanjaykumar Hapani, et al.
Pageof 1

Showing results (1-10 of 9) with videos related to

Sort By:
Pageof 1
The New England Journal of Medicine|June 28, 2013
Images in clinical medicine. Enlarged spleen with a heterogeneous patternRosa Nouvini, Sanjaykumar Hapani
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 4, 2011
Controversial role of bevacizumab in the development of venous thromboembolic eventsSanjaykumar Hapani, Shenhong Wu
Journal of Medical Case Reports|May 1, 2010
Eosinophilic pneumonia associated with bleomycin in a patient with mediastinal seminoma: a case reportSanjaykumar Hapani, David Chu, Shenhong Wu
The Lancet. Oncology|June 2, 2009
Risk of gastrointestinal perforation in patients with cancer treated with bevacizumab: a meta-analysisSanjaykumar Hapani, David Chu, Shenhong Wu
JAMA|February 3, 2011
Treatment-related mortality with bevacizumab in cancer patients: a meta-analysisVishal Ranpura, Sanjaykumar Hapani, Shenhong Wu
Acta Oncologica (Stockholm, Sweden)|February 17, 2010
Risk of cardiac ischemia and arterial thromboembolic events with the angiogenesis inhibitor bevacizumab in cancer patients: a meta-analysis of randomized controlled trialsVishal Ranpura, Sanjaykumar Hapani, Jeff Chuang, et al.
Oncology|November 6, 2010
Increased risk of serious hemorrhage with bevacizumab in cancer patients: a meta-analysisSanjaykumar Hapani, Amna Sher, David Chu, et al.
Acta Oncologica (Stockholm, Sweden)|April 19, 2013
Risk of liver toxicity with the angiogenesis inhibitor pazopanib in cancer patientsSamir Kapadia, Sanjaykumar Hapani, Toni K Choueiri, et al.
Journal of General Internal Medicine|November 27, 2012
Test results follow-up: a systematic reviewShai Gavi, Vishal Ranpura, Sanjaykumar Hapani, et al.
Pageof 1